ChronicleBio

Menlo Park, California, USA · ≈22 employees · chroniclebio.com

ChronicleBio is a biotechnology research company founded in 2025 and based in San Francisco. The company specializes in AI-powered data platforms aimed at accelerating diagnostics, treatments, and research for neuroimmune disorders and complex chronic conditions, including POTS, ME/CFS, Long COVID, MCAS, persistent Lyme, and Sjogren’s. With a small team, ChronicleBio operates a decentralized research ecosystem that collects biospecimens and generates multi-omic datasets, creating an adaptive, AI-ready data lake. The company's core offering is a comprehensive data platform that integrates multi-omic datasets from various sources, including biospecimens and wearable data. ChronicleBio employs AI-driven tools to support real-world discovery, enabling insights into disease models, diagnostics, and clinical trial opportunities. The firm collaborates with patients, clinicians, researchers, and pharmaceutical companies to advance research and fill gaps in standards of care for conditions affecting over 250 million people globally.